SG10201406846XA - Bisphosphonate compounds for treating bone metabolism disorders - Google Patents

Bisphosphonate compounds for treating bone metabolism disorders

Info

Publication number
SG10201406846XA
SG10201406846XA SG10201406846XA SG10201406846XA SG10201406846XA SG 10201406846X A SG10201406846X A SG 10201406846XA SG 10201406846X A SG10201406846X A SG 10201406846XA SG 10201406846X A SG10201406846X A SG 10201406846XA SG 10201406846X A SG10201406846X A SG 10201406846XA
Authority
SG
Singapore
Prior art keywords
compounds
treating bone
bone metabolism
metabolism disorders
bisphosphonate compounds
Prior art date
Application number
SG10201406846XA
Inventor
Frank Hallock Ebetino
Adam Wieslaw Mazur
Roy Lee Martin Dobson
Original Assignee
Warner Chilcott Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co Llc filed Critical Warner Chilcott Co Llc
Publication of SG10201406846XA publication Critical patent/SG10201406846XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Abstract

257 Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism. Fig: None
SG10201406846XA 2009-10-26 2010-10-26 Bisphosphonate compounds for treating bone metabolism disorders SG10201406846XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25488609P 2009-10-26 2009-10-26

Publications (1)

Publication Number Publication Date
SG10201406846XA true SG10201406846XA (en) 2014-12-30

Family

ID=43478185

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201406846XA SG10201406846XA (en) 2009-10-26 2010-10-26 Bisphosphonate compounds for treating bone metabolism disorders

Country Status (10)

Country Link
US (3) US8314081B2 (en)
EP (1) EP2493905B1 (en)
JP (1) JP5850842B2 (en)
CN (1) CN102630227B (en)
CA (1) CA2778015C (en)
IL (1) IL219235A (en)
IN (1) IN2012DN03448A (en)
MX (1) MX2012004769A (en)
SG (1) SG10201406846XA (en)
WO (1) WO2011056589A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN03448A (en) 2009-10-26 2015-10-23 Warner Chilcott Co Llc
EP2800561B1 (en) * 2012-01-06 2020-08-19 Anji Pharma (US) LLC Biguanide compositions and methods of treating metabolic disorders
JP2017512183A (en) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド Prodrug compounds and their use
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2043072B (en) 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
DE3640938A1 (en) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND
JPH0699457B2 (en) * 1988-08-12 1994-12-07 山之内製薬株式会社 Heterocyclic bisphosphonic acid derivative and its medicine
US4990503A (en) 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
US5039699A (en) * 1989-03-27 1991-08-13 Lederle (Japan), Ltd. Anti-peptic ulcer agent
US5227506A (en) 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI89366C (en) * 1990-12-20 1993-09-27 Leiras Oy Process for the preparation of novel pharmacologically useful methylenebisphosphonic acid derivatives
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
CA2102303A1 (en) * 1991-06-19 1992-12-20 Roy Allen Johnson Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
JPH05239075A (en) * 1991-08-27 1993-09-17 Eisai Co Ltd Phosphorus-containing isoprenoid derivative
JPH06172372A (en) * 1991-11-06 1994-06-21 Takeda Chem Ind Ltd Squalene synthetase inhibitor and its use
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
WO1994020508A1 (en) * 1993-03-08 1994-09-15 Eisai Co., Ltd. Phosphonic acid derivatives
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
EP0705834A1 (en) 1994-07-27 1996-04-10 Ciba-Geigy Ag Quinoxaline-2,3-diones with an azaheterocyclic fused ring
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7781418B2 (en) 2006-12-14 2010-08-24 Isis Innovation Ltd. Composition for treating bone disorders
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
US8252774B2 (en) 2008-09-22 2012-08-28 Isis Innovation Ltd. 5-azaindole bisphosphonates
EP2350076B1 (en) 2008-09-22 2013-08-21 Isis Innovation Ltd Imidazo[1,2- alpha]pyridinyl bisphosphonates
IN2012DN03448A (en) 2009-10-26 2015-10-23 Warner Chilcott Co Llc

Also Published As

Publication number Publication date
EP2493905B1 (en) 2016-11-30
MX2012004769A (en) 2012-08-08
WO2011056589A1 (en) 2011-05-12
CN102630227A (en) 2012-08-08
US8822435B2 (en) 2014-09-02
US20130035482A1 (en) 2013-02-07
CA2778015C (en) 2016-08-02
JP5850842B2 (en) 2016-02-03
CA2778015A1 (en) 2011-05-12
IL219235A (en) 2017-01-31
EP2493905A1 (en) 2012-09-05
US20110098251A1 (en) 2011-04-28
US8710215B2 (en) 2014-04-29
CN102630227B (en) 2016-03-23
JP2013508459A (en) 2013-03-07
IN2012DN03448A (en) 2015-10-23
US8314081B2 (en) 2012-11-20
IL219235A0 (en) 2012-06-28
US20140194389A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
IN2014DN09805A (en)
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2014DN09804A (en)
EA201290482A1 (en) STABLE COMPOSITIONS FOR LIOPHILIZATION OF THERAPEUTIC PARTICLES
UA109868C2 (en) N -alkyltriazole compounds asr
IN2012DN02735A (en)
IN2012DN00754A (en)
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MX2019000547A (en) Stabilized liquid and lyophilized adamts13 formulations.
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
WO2010033978A3 (en) IMIDAZO[1,2-α ]PYRIDINYL BISPHOSPHONATES
WO2011023367A3 (en) Bisphosphonate-prodrugs
MX337849B (en) Compositions and methods for inhibition of the jak pathway.
MX2012004548A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX342119B (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
SG10201406846XA (en) Bisphosphonate compounds for treating bone metabolism disorders
MX2011008645A (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase.
WO2010033980A3 (en) 4-azaindole bisphosphonates
WO2010033981A3 (en) 5-azaindole bisphosphonates
MX2009011577A (en) Compositions and methods for transmucosal delivery of domperidone.
MX360235B (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor.